Consistent with these results, our recent studies have shown that LIMD1 is induced by NFκB and IRF4 downstream of the signaling pathway triggered by the EBV principal oncoprotein LMP1 in EBV-transformed LCLs, suggesting that LIMD1 could serve as an oncogenic biomarker in association with NFκB and IRF4 in certain hematological malignancies (11, 12). Here, NFKB1 is linked to hematologic disorder.